Celerion
Lincoln, Nebraska, 68502, United States
NCT Number: NCT02639078
Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-0714 in healthy subjects.
Looking for future studies?
Notify Me19 year–55 year
All sexes
Interventional
Phase 1
Lincoln, Nebraska, 68502, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One time dosing in capsule formulation
One time dosing in capsule formulation
Time frame: From Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: The day before dosing (Day -1) to the day after dosing (Day 2)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: Day 1 through end of study (Day 10)
Time frame: The day before dosing (Day -1) to the day after dosing (Day 2)
Time frame: The day before dosing (Day -1) to the day after dosing (Day 2)
Time frame: The day before dosing (Day -1) to the day after dosing (Day 2)
Time frame: The day before dosing (Day -1) to the day after dosing (Day 2)
Theravance Biopharma
Industry
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD-0714 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details